EWTX Edgewise Therapeutics, Inc.

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was founded in 2017 and is headquartered in Boulder, Colorado.

$17.41  -0.88 (-4.81%)
As of 11/30/2021 15:59:55 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  12/15/2009
Outstanding shares:  49,295,840
Average volume:  159,891
Market cap:   $1,004,649,219
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    28036F105
ISIN:        US28036F1057
Sedol:      BKY5JZ8
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   3.16
PS ratio:   0.00
Return on equity:   -12.77%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy